Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).

Louise Emmett; Sarennya Pathmanandavel; Megan Crumbaker; Christopher Rofe; Andrew On Wah Yam; Bao Ho; Wai Ling Chan; Shikha Sharma; Joanne Keane; Adam James Hickey; Karen Fullard; Kamonwan Kongrak; Lalith Ratnayake; John A Violet; Arun Azad; Peter Eu; Andrew Nguyen; Anthony M Joshua

Conference Proceedings

Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).

Louise Emmett, Sarennya Pathmanandavel, Megan Crumbaker, Christopher Rofe, Andrew On Wah Yam, Bao Ho, Wai Ling Chan, Shikha Sharma, Joanne Keane, Adam James Hickey, Karen Fullard, Kamonwan Kongrak, Lalith Ratnayake, John A Violet, Arun Azad, Peter Eu, Andrew Nguyen, Anthony M Joshua

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020

DOI: 10.1200/jco.2020.38.15_suppl.5557

Abstract

5557 Background: There is no established standard of care post cabazitaxel in men with mCRPC. Ongoing trials in 177LuPSMA-617 have demonstrated good efficacy and safety, but synergistic combinations may further improve treatment responses. Idronoxil (NOX66) inhibits external NADH oxidase type 2 with downstream pro-apoptotic actions including radio-sensitization. Herein we present updated results and an additional cohort of a prospective single arm phase I/II dose escalation/expansion trial of LuPSMA-617 and NOX66 in mCRPC. Methods: Men with progressive mCRPC post androgen signalling inhibition (ASI) and 2 lines of taxane chemotherapy were considered eligible. Key inclusion criteria included..

View full abstract